Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Bosutinib (Primary) ; Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary) ; Pembrolizumab (Primary)
Indications Chronic myeloid leukaemia
Focus Therapeutic Use
Acronyms Blast MRD CML 1 Trial

27 Nov 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Aug 2028.
29 Dec 2021 Planned primary completion date changed from 31 Aug 2021 to 31 Dec 2023.
14 Dec 2021 Interim Results (data cut-off date June 15th, 2021, n=6) from safety cohort, presented at the 63rd American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com